Illinois-based Surgisphere Corporation had a brief moment in the limelight this year following its infamous study of hydroxychloroquine. But the impact of the company’s deception reverberated across world.
The high-profile retractions of two COVID-19 studies stunned the scientific community earlier this year and prompted calls for reviews of how science is conducted, published, and acted upon. The warning signs had been there all along.
The company behind a now-discredited study on hydroxychloroquine also posted a report that has been cited by Latin American governments recommending ivermectin as a possible coronavirus treatment. Clinicians there say the effects have been extremely damaging.
The company had helped develop a tool to aid decision-making in distributing limited medical equipment among coronavirus patients, but two high-profile retractions call into question the validity of Surgisphere’s work in toto.
Scientists have raised questions about the dataset published in The Lancet last week that triggered the suspension of clinical trials around the world—and about Surgisphere Corporation, the company behind the study.